In vivo efficacy studies of chromene-based compounds in triple-negative breast cancer - A systematic review.
Triple-negative breast cancer (TNBC) is considered the most aggressive breast cancer subtype, shows a poor response to the currently available therapy, and has no targeted therapy. Chemotherapy, surgery and radiation are the current therapeutic options to treat patients with TNBC, however, response to these therapeutic approaches is very poor and has significant side effects. Thus, there is an urgent need to search for new anti-TNBC agents, more effective and safer than current therapy. A wide range of synthetic chromene derivatives have been explored as anticancer agents in different cancer models, with promising results, and some of them already reached the clinical setting. Especially in TNBC, most of the available studies are conducted in in vitro models, with limited results in vivo. It is important the activity of any new compound that reaches clinical studies is supported by solid pre-clinical data. Thus, in the present study, we review and analyze the studies that use chromene-based compounds using in vivo models of TNBC. The results of this systematic review can add value to ongoing chromene-based studies.
['Oliveira-Pinto|Sofia|S|', 'Pontes|Olívia|O|', 'Baltazar|Fátima|F|', 'Costa|Marta|M|']
D000818:Animals D000970:Antineoplastic Agents D001578:Benzopyrans D014408:Biomarkers, Tumor D005260:Female D006801:Humans D058990:Molecular Targeted Therapy D064726:Triple Negative Breast Neoplasms
Chromene-based compounds Triple-negative breast cancer Cancer Systematic review In vivo studies